Skip to main content
Erschienen in: Familial Cancer 1/2018

16.05.2017 | Original Article

Next generation sequencing is informing phenotype: a TP53 example

verfasst von: R. O’Shea, R. Clarke, E. Berkley, C. Giffney, M. Farrell, E. O’Donovan, D. J. Gallagher

Erschienen in: Familial Cancer | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

The increased availability of next generation sequencing (NGS) and multi gene panel testing has resulted in more frequent TP53 testing of families that do not meet classic testing criteria. We investigated testing criteria, family history and result outcome in a cohort of Irish probands undergoing TP53 full sequencing. All TP53 test requests processed through the national genetic testing laboratory between 2012 and 2014 were retrospectively reviewed. Personal and family cancer histories were collected, including tumour type and age at diagnosis, from two adult cancer genetic services in Ireland. Association between Li Fraumeni syndrome (LFS) or Li Fraumeni like syndrome (LFL) criteria and test result was examined. One hundred and 35 TP53 test requests were identified. Family history data and test results were available on 123 of the TP53 test requests (118 female; 5 male). 59/123 (48%) did not meet classic LFS or LFL criteria. Two individuals from this group harboured pathogenic TP53 mutations, giving a 3% mutation detection rate in those not meeting testing criteria. Both were female and had a personal history of early onset bilateral breast cancer with no reported LFS cancers in the family. 64/123 (52%) met LFS or LFL criteria and were all TP53 negative. 37/64 (57.8%) met Chompret criteria, 19/64 (29.7%) met Eeles and 7/64 (10.9%) met Eeles and Chompret and 1/64 (1.6%) met Classic LFS criteria. Stringent testing criteria miss germline mutations in TP53. Broadening the criteria for TP53 testing may improve our understanding of the phenotype and penetrance in the association syndrome.
Literatur
1.
Zurück zum Zitat Kamihara J, Rana HQ, Garber JE (2014) Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 35(6):654–662CrossRefPubMed Kamihara J, Rana HQ, Garber JE (2014) Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 35(6):654–662CrossRefPubMed
2.
Zurück zum Zitat Sorrell AD, Espenschield CR, Culver JO, Weitzel JN (2013) TP53 testing and Li-Fraumeni syndrome: current status of clinical applications and future directions. Mol Diagn Ther 17(1):31–47CrossRefPubMedPubMedCentral Sorrell AD, Espenschield CR, Culver JO, Weitzel JN (2013) TP53 testing and Li-Fraumeni syndrome: current status of clinical applications and future directions. Mol Diagn Ther 17(1):31–47CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Gonzalez KD, Nolter KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN (2009) Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250–1256CrossRefPubMed Gonzalez KD, Nolter KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN (2009) Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250–1256CrossRefPubMed
4.
Zurück zum Zitat Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362PubMed Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362PubMed
5.
Zurück zum Zitat Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298–1304PubMed Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298–1304PubMed
6.
Zurück zum Zitat Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surviv 25:101–124 Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surviv 25:101–124
7.
Zurück zum Zitat Tinat J, Bougeard G, Baert-Desurmont S et al (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27(26):108–109CrossRef Tinat J, Bougeard G, Baert-Desurmont S et al (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27(26):108–109CrossRef
8.
Zurück zum Zitat Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugieres L, Caron O, Benusiglio PR, Bressac de Paillerets B, Bonadona V, Bonaiti-Pellie C, Tinat J, Baert-Desurmont S, Frebourg T (2015) Revisiting Li-Fraumeni syndrome from TP53 carriers. J Clin Oncol 33:2345–2352CrossRefPubMed Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugieres L, Caron O, Benusiglio PR, Bressac de Paillerets B, Bonadona V, Bonaiti-Pellie C, Tinat J, Baert-Desurmont S, Frebourg T (2015) Revisiting Li-Fraumeni syndrome from TP53 carriers. J Clin Oncol 33:2345–2352CrossRefPubMed
9.
Zurück zum Zitat Chrompret A, Brugieres L, Ronsin M et al (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932–1937CrossRef Chrompret A, Brugieres L, Ronsin M et al (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932–1937CrossRef
10.
Zurück zum Zitat Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, Sommer SS (2009) High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 46:689–693CrossRefPubMed Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, Sommer SS (2009) High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 46:689–693CrossRefPubMed
11.
Zurück zum Zitat Schneider K, Garber J (1993) Li-Fraumeni syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (eds) GeneReviews, University of Washington, Seattle, Seattle Schneider K, Garber J (1993) Li-Fraumeni syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (eds) GeneReviews, University of Washington, Seattle, Seattle
12.
Zurück zum Zitat Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614CrossRefPubMed Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614CrossRefPubMed
13.
14.
Zurück zum Zitat Evans DGR, Moran A, Hartley R, Dawson J, Bulman B, Knox F, Howell A, Lalloo F (2010) Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA I/BRCA2/TP53 status. Br J Cancer 102:1091–1098CrossRefPubMedPubMedCentral Evans DGR, Moran A, Hartley R, Dawson J, Bulman B, Knox F, Howell A, Lalloo F (2010) Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA I/BRCA2/TP53 status. Br J Cancer 102:1091–1098CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Lalloo F, Varley J, Moran A, Ellis D, O’Dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42:1143–1150CrossRefPubMed Lalloo F, Varley J, Moran A, Ellis D, O’Dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42:1143–1150CrossRefPubMed
17.
Zurück zum Zitat Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70:4795–4800CrossRefPubMedPubMedCentral Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70:4795–4800CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, Robidoux A, Londono J, Vasquez G, Gomes M, Costa MM, Dimitrakakis C, Gutierrez G, Pilarski R, Royer R, Narod SA (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8:563e7CrossRef Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, Robidoux A, Londono J, Vasquez G, Gomes M, Costa MM, Dimitrakakis C, Gutierrez G, Pilarski R, Royer R, Narod SA (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8:563e7CrossRef
19.
Zurück zum Zitat Borresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D, et al (1992). Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52:3234e6 Borresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D, et al (1992). Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52:3234e6
20.
Zurück zum Zitat Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. (1992) p53 mutations in breast cancer. Cancer Res 52:5291e8 Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. (1992) p53 mutations in breast cancer. Cancer Res 52:5291e8
21.
Zurück zum Zitat Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B, Davidson N (1992) Inherited p53 gene mutations in breast cancer. Cancer Research 52:2984e6 Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B, Davidson N (1992) Inherited p53 gene mutations in breast cancer. Cancer Research 52:2984e6
22.
Zurück zum Zitat Ruijis MWG, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst F, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems M, Hoogerbrugge N, van Asperen CJ, Gomez Garcia E, Meijers-Heijboer H, ten Kate LP, Menko FH, van’t Veer LJ (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47:421–428CrossRef Ruijis MWG, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst F, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems M, Hoogerbrugge N, van Asperen CJ, Gomez Garcia E, Meijers-Heijboer H, ten Kate LP, Menko FH, van’t Veer LJ (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47:421–428CrossRef
23.
Zurück zum Zitat Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S (2006) Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 130:73–79CrossRefPubMed Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S (2006) Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 130:73–79CrossRefPubMed
24.
Zurück zum Zitat Masciari S, Dillon DA, Rath M et al (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 133(3):2984–2986CrossRef Masciari S, Dillon DA, Rath M et al (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 133(3):2984–2986CrossRef
25.
Zurück zum Zitat Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, Garber JE (2013) Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat 139:193–198.CrossRefPubMedPubMedCentral Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, Garber JE (2013) Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat 139:193–198.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Melhem-Bertrandt A, Bojadzieva J, Ready KJ et al (2012) Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908–913CrossRefPubMed Melhem-Bertrandt A, Bojadzieva J, Ready KJ et al (2012) Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908–913CrossRefPubMed
27.
Zurück zum Zitat Silva AG, Ewald IP, Sapienza M, Pinheiro M, Peixoto A, de Nobrega AF, Carraro DM, Teixeira MR, Ashton-Prolla P, Achatz MI, Rosenberg C, Krepischi AC (2012) Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion. BMC Cancer 12:237CrossRefPubMedPubMedCentral Silva AG, Ewald IP, Sapienza M, Pinheiro M, Peixoto A, de Nobrega AF, Carraro DM, Teixeira MR, Ashton-Prolla P, Achatz MI, Rosenberg C, Krepischi AC (2012) Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion. BMC Cancer 12:237CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME (2013) Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 31:1267–1270CrossRefPubMed Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME (2013) Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 31:1267–1270CrossRefPubMed
29.
Zurück zum Zitat Peterson SK, Pentz RD, Marani SK et al (2008) Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome. Psychooncology 17(8):783–789CrossRefPubMed Peterson SK, Pentz RD, Marani SK et al (2008) Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome. Psychooncology 17(8):783–789CrossRefPubMed
30.
Zurück zum Zitat Lammens CR, Aaronson NK, Wagner A et al (2010) Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 28(18):3008–3014CrossRefPubMed Lammens CR, Aaronson NK, Wagner A et al (2010) Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 28(18):3008–3014CrossRefPubMed
31.
Zurück zum Zitat Lammens CR, Bleiker EM, Verhoef S et al (2011) Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes. Psychooncology 20(6):631–638CrossRefPubMed Lammens CR, Bleiker EM, Verhoef S et al (2011) Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes. Psychooncology 20(6):631–638CrossRefPubMed
32.
Zurück zum Zitat Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF Jr, Syngal S, Garber JE (2008) F18-fluorodeoxyglucosepositron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 299:1315–1319CrossRefPubMed Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF Jr, Syngal S, Garber JE (2008) F18-fluorodeoxyglucosepositron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 299:1315–1319CrossRefPubMed
33.
Zurück zum Zitat Villani A, Tabori U, Schiffman J et al (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 12(6):559–567CrossRefPubMed Villani A, Tabori U, Schiffman J et al (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 12(6):559–567CrossRefPubMed
Metadaten
Titel
Next generation sequencing is informing phenotype: a TP53 example
verfasst von
R. O’Shea
R. Clarke
E. Berkley
C. Giffney
M. Farrell
E. O’Donovan
D. J. Gallagher
Publikationsdatum
16.05.2017
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 1/2018
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0002-1

Weitere Artikel der Ausgabe 1/2018

Familial Cancer 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.